gear growth
bonesupport emerg transit year result highlight
progress invest implement commerci initi acceler global
cerament penetr switch direct sale octob prior suppli
issu exclus distributor impact us sale vs sek
europe/row deliv strong sale growth high
margin antibiot elut product continu gain traction anticip increas
sale expand global commerci footprint bed key clinic
data eg certifi leverag new us gpo contract secur
provid solid foundat compani achiev target revenu
growth onward valu bonesupport sek
european salesforc expans bear fruit bonesupport
sale team europ follow recruit plan new
hire broader increas use cerament g/v import sale
driver market share continu build osteomyel traction start
gain trauma impact new rep expect felt
coupl increas confer presenc leverag certifi trauma
data improv sale key european market germani
us commerci infrastructur set deliv sek us sale gener
first week direct market cerament bvf via network
independ us distributor sale rep gpo contract critic
market access ahead manag expect first contract
secur complet rep train improv market
access launch complementari collagen matrix/mtf biolog product
significantli boost us sale beyond form strong
commerci base potenti launch cerament
build bodi evid key paper major scientif journal
expect firstli detail certifi data demonstr cerament bvf
non-inferior gold standard autograft treat fractur defect secondli
data five-year nuffield health econom studi data import
market reimburs also posit bonesupport favour ahead
may implement new eu medic devic regul
sek valuat updat three-phas dcf
model back result valuat employ conserv
assumpt sek near-
term upsid potenti come greater visibl strateg execut us
sale acceler long-term data pivot fortifi studi view
key growth driver
share issu
bonesupport swedish ortho-
biolog compani focus
develop commercialis
pipelin uniqu inject drug
substitut base proprietari
bonesupport emerg year transit
anticip import year bonesupport
strateg transform come fruition lay foundat achiev
manag target year-on-year sale growth onward
variou commerci initi implement detail
octob capit market day updat note goal acceler market
penetr cerament variou geographi result evid
strateg evolut new us commerci structur increas albeit
focus invest sale market compani continu
execut plan expect repres sale inflect point
valu bonesupport
transit complet
commerci platform set
deliv
bonesupport presenc us europe/row synthet bone graft market
differ market dynam histor quarterli sale shown exhibit
region summaris key achiev later note
howev focu firmli drive market penetr
cerament revenu growth
cerament well place
clear differenti robust
import us market
key market europ
address sizeabl sale team
cerament posit synthet bone graft substitut industri
lead clinic data highlight abil remodel patient bone
case cerament elut antibiot directli bone
void protect heal process data critic commun valu
proposit novel product platform surgeon patient payor
avail full data certifi trauma studi expect publish
lead journal provid strong impetu front
us sale benefit direct distribut network becom fulli
effect sale rep complet initi train done date
market access improv new gpo contract secur complementari
osteobiolog product collagen matrix mtf biolog collabor
launch europ larger commerci focus sale
team also start make signific inroad geograph area
larg orthopaed centr previous limit sale presenc
prioriti trauma osteomyel indic
exhibit quarterli sale progress us europe/row
triniti delta shift under-perform
exclus distributor multipl
independ execut
us notabl achiev
cerament bvf current avail bonesupport product us
net sale sek sale
mute previou exclus distributor zimmer biomet experienc
signific hardwar suppli issu termin distribut agreement
switch direct sale model octob meant bonesupport
book sale although revenu gener
corpor perspect highli success achiev
numer object meaning sale data expect
distribut network place network independ
distributor sale rep
rep train educ underway train on-going process
howev rep complet initi sale train
remaind expect done
initi sale meet manag expect octob
mark first sale exist custom suppli chain
issu happen subsequ custom establish
new cerament user sale far line
manag expect focu custom convers
includ area zimmer biomet limit rep coverag
bonesupport access bone graft substitut
market vs zimmer biomet
gpo contract gpo contract essenti access us
market first major win hospit corpor
america cover care site previous
limit access secur ahead schedul sale expect
come month manag optimist
contract
europe/row focus approach
europe/row continu show revenu growth net sale
increas sek specif europ strong
momentum cerament sale
major contributor growth sale gener five
direct european market uk germani switzerland sweden denmark
bonesupport provid geograph breakdown disclos
us germani uk market repres
net sale
bonesupport increas presenc medic confer
expand european sale market organis
plan new hire place find train
right individu rate limit step defin quickli commerci
impact felt hire train focus deploy initi custom contact
new rep prioriti sale impact expect come
invest european sale infrastructur reap
reward rel short time-frame new hire experienc
deploy key region import orthopaed centr
europ start benefit
invest stronger sale team
key direct market
bonesupport histor limit presenc guid manag
suggest first month new rep expect
gener sale middl rang
bonesupport also direct resourc toward under-penetrated market
germani trauma clear prioriti
certifi trauma data germani
convinc clinic outcom
robust certifi studi
least good autograft
current gold standard
without risk cost
clinic evid
germani largest market bone graft substitut europ
eight-person sale team task increas penetr
metropolitan area univers hospit
cerament g/v account european sale
establish foothold chronic osteomyel howev complex trauma
under-penetrated larger market opportun
ground-break level clinic data certifi studi cerament
treatment fractur defect studi could catalys increas sale germani
trauma germani conserv market strict requir
clinic data henc certifi result could disproportion impact
studi confirm non-inferior cerament bvf autograft fact
run german trauma centr provid familiar cerament
product suit cerament bvf could entri point increas use
cerament g/v ad clinic health econom benefit
lower risk infect hospit readmiss high risk injuri
build bodi compel clinic evid
top line data certifi releas novemb show
cerament bvf non-inferior autograft treat fractur defect certifi
prospect randomis control studi evalu patient
across german trauma centr compar outcom cerament bvf
autograft patient deriv bone treat tibial plateau fractur
autograft consid gold standard high efficaci safeti howev
need two surgic procedur harvest transplant increas
cost vs altern pain associ infect risk fact
cerament bvf shown clinic non-inferior
requir singl procedur reduc surgeri time risk infect
could increas address market opportun potenti long-term
paradigm shift standard care trauma accord compani
autograft current account annual procedur bone graft
us even modest captur market share would signific
bonesupport compet synthet bone graft substitut level
randomis clinic data cerament would also first-mov advantag
certifi result add grow bodi evid support cerament
bonesupport key opinion leader kol network continu bolster
case studi present peer review public recent
larg anim model pilot studi long-term pk studi cerament
vancomycin releas hip surgeri
depth breadth support clinic data document
cerament mean bonesupport well-prepar end transit
period full implement eu medic devic regul may
regul put stringent oblig manufactur ensur
qualiti perform safeti medic devic includ
clinic evid support product claim full implement may also trigger
shift competit dynam european market smaller
produc run difficulti meet requir
anoth import facet address health econom outcom research
help drive reimburs data studi led
nuffield orthopaed centr oxford univers hospit also expect
publish initi data posit indic use
cerament osteomyel reduc surgic time procedur rate
compar full rang altern treatment avail england
financi valuat
bonesupport report net sale decreas
decreas primarili attribut disrupt us
market caus suppli issu zimmer biomet follow
switch direct distribut model octob us net sale
gross margin europe/
row sale grew overal gross
margin particularli strong growth cerament g/v sale vs
due reduc us revenu gross profit
expenditur increas reflect bonesupport focus invest
initi acceler sale cerament product higher sell expens
incur switch direct
sale model us european sale forc expans increas
market activ global spend increas modestli
admin expens sek broadli flat
wider oper loss sek sek net loss
sek result combin lower overal
revenu coupl increas albeit focus invest
bonesupport end decemb cash equival
accord manag suffici runway profit posit
cash flow achiev respect accord model
result updat forecast exhibit valuat model
stage given near-term uncertainti around us cerament bvf
sale ramp made minor tweak expect expect
revis revenu forecast later sale trajectori becom
better establish sale rep receiv train inform
avail progress gpo contract highlight bonesupport
begin exclus promot cerament bvf us april
point level inventori still held zimmer biomet becom
irrelev line bonesupport focu disciplin cost control balanc
appropri invest realloc admin expens sale
exhibit summari chang estim
chang forecast flow valuat model updat
valuat reflect strengthen sek/u vs previous
number share outstand last report cash well roll forward
model reflect passag time three-stag dcf methodolog
valu bonesupport sek vs previous
valuat base explicit cash flow follow ten-year
trend period termin growth rate forecast sale
current market cerament product europe/row us also
includ cerament us latter assum launch
appli risk adjust recognis clinic regulatori risk individu
product rnpv sum net cost run busi
exhibit provid detail breakdown compon valuat
exhibit dcf-base valuat bonesupport
likelihood
net cash
triniti delta note assum usd/sek exchang rate
continu success execut eg commerci traction and/or success
addit product would unlock upsid potenti impact certifi
trajectori bvf sale trauma us approv cerament
two key inflect point latter remov risk adjust
cerament us would lift valuat sek
addit continu appli discount rate reflect fact
bonesupport small compani oper highli competit market use
less conserv discount rate result sek sek
exhibit summari financi
compani triniti delta note histor adjust number share follow
consolid
triniti deltayear-end dec good oper profit financ tax incom ep share marginn/an/an/an/an/abal sheetcurr cash current plant non-curr current non-curr statementsoper cash work cash invest cash cash financ cash increas rate start end cash end
triniti delta research limit tdrl firm refer number trade triniti delta appoint repres
equiti develop limit ed content report prepar sole responsibil iti tdrl
review independ verifi ed authoris regul fca whose refer number
ed act tdrl person respons provid protect provid client tdrl
advis person connect content report except extent requir applic abl law
includ rule fca owe duti care person lianc may place ed advic
recommend respect content report extent may applic law ed make
represent warranti person read report regard inform contain
prepar report tdrl use public avail sourc taken reason effort ensur fact state
herein clear fair mislead make guarante warranti accuraci complet inform
opinion contain herein provid updat fresh inform becom avail opinion chang
person relev person section section financi servic market act un ite
kingdom act reli document content research client compani produc tdrl normal
commiss paid compani issuer financ research deem independ
defin fca object author state opinion report consid market
commun purpos fca rule prepar accord legal requiremen ts design promot
independ invest research subject prohibit deal ahead dissemin investm ent research
tdrl hold posit compani mention report although director employe consult tdrl
may hold posit compani mention tdrl impos restrict person deal tdrl might also provid servic
compani mention solicit busi
report provid relev person provid background inform subject matter note document
constitut form part constru offer sale purchas solicit invit
make offer buy sell secur may rise fall valu shall part form ba reli
connect contract commit whatsoev inform provid intend
manner whatsoev constru personalis advic self-certif investor complet free charg
www fisma org tdrl affili offic director employe ed liabl loss damag aris use
document maximum extent law permit
inform avail websit www trinitydelta org
